Published in Artif Cells Nanomed Biotechnol on July 31, 2014
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA (2004) 7.04
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ (2006) 5.90
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
HIV drug resistance. N Engl J Med (2004) 5.52
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep (2005) 5.03
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS (2007) 4.74
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr (2002) 4.39
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Public health. HIV testing in China. Science (2006) 3.58
Effectiveness of condoms in preventing HIV transmission. Soc Sci Med (1997) 3.56
Factors affecting adherence to antiretroviral therapy. Clin Infect Dis (2000) 3.47
Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS (2004) 3.46
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med (2005) 3.27
HIV/AIDS stigma: an impediment to public health. Am J Public Health (2002) 3.08
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS (1999) 2.82
Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev (2006) 2.81
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62
Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS (2002) 2.57
Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis (2010) 2.57
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Stigma, social support, and depression among people living with HIV in Thailand. AIDS Care (2009) 2.31
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
"I have an evil child at my house": stigma and HIV/AIDS management in a South African community. Am J Public Health (2005) 2.24
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23
A comparison of HIV stigma and discrimination in five international sites: the influence of care and treatment resources in high prevalence settings. Soc Sci Med (2009) 2.22
Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev (2012) 2.22
Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group. J Acquir Immune Defic Syndr (2000) 2.19
Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 2.15
Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep (2008) 2.09
Is the influence of social desirability on patients' self-reported adherence overrated? J Acquir Immune Defic Syndr (2004) 2.03
Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care (2008) 2.01
The HIV epidemic in China: history, response, and challenge. Cell Res (2005) 1.92
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.88
Understanding the social and cultural contexts of female sex workers in Karnataka, India: implications for prevention of HIV infection. J Infect Dis (2005) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Understanding HIV-related stigma and discrimination in a "blameless" population. AIDS Educ Prev (2006) 1.78
Ethical issues in epidemiologic research and public health practice. Emerg Themes Epidemiol (2006) 1.69
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice. J Acquir Immune Defic Syndr (2010) 1.64
AIDS epidemic at age 25 and control efforts in China. Retrovirology (2006) 1.50
Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behaviour among HIV-infected homosexual men. AIDS (2004) 1.43
Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS (2000) 1.43
Management of HIV-related stigma and adherence to HAART: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003). AIDS Care (2006) 1.41
Increase in HIV sexual risk behaviour in homosexual men in Scotland, 1996-2002: prevention failure? Sex Transm Infect (2005) 1.41
South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med (2007) 1.40
Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr (2002) 1.40
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.34
Effectiveness of a PMTCT programme in rural Western Kenya. AIDS Care (2011) 1.32
Primaquine for prevention of malaria in travelers. Clin Infect Dis (2003) 1.31
Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev (2009) 1.29
Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Am J Prev Med (1998) 1.22
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med (1998) 1.19
Adherence to an exercise prescription scheme: the role of expectations, self-efficacy, stage of change and psychological well-being. Br J Health Psychol (2005) 1.15
Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis (1997) 1.07
Discrimination against people with HIV persists in China. Lancet (2011) 1.05
HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med (2012) 1.03
Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med (2013) 1.00
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol (2000) 1.00
Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology (2004) 0.96
Will sexual risk behaviour increase after being vaccinated for AIDS? Int J STD AIDS (2006) 0.92
The road to an effective HIV vaccine. N Engl J Med (2012) 0.84
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. Clin Infect Dis (2005) 0.79
Trial and failure. Nature (2007) 0.78
Public health service task force updates recommendations for use of antiretroviral drugs in pregnant women. Hopkins HIV Rep (2000) 0.75